Literature DB >> 10940762

Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality.

S Oberndorfer1, G Saletu-Zyhlarz, B Saletu.   

Abstract

The purpose of this paper is to review the effects of selective serotonin (5-HT) reuptake inhibitors on objective and subjective sleep and awakening quality measures. Polysomnography (PSG) demonstrated in both healthy volunteers and depressed patients a decrease in sleep efficiency and total sleep time, a lengthening of sleep latency and a deterioration in sleep continuity, including an increase in the number of awakenings and wake time during the total sleep period. Sleep architecture mostly showed an increase in S1 and S2 and a decrease in S3, S4 and REM sleep as well as a lengthening of REM latency. Objective awakening quality, if measured at all by psychometry, generally showed no decrements. Concerning subjective sleep and awakening quality, normals demonstrated either no changes or a tendency towards a deterioration, while in patients some improvement was observed. Reasons for this discrepancy will be discussed. Novel 5-HT reuptake inhibitors with additional modes of action such as 5-HT2 antagonism (e.g. trazodone, nefazodone) are more likely to improve objective and subjective sleep quality, although some shortcomings may be inherent in regard to comorbidity (e.g. sleep-related breathing disorders). Thus, PSG seems to be a necessity for diagnosis and treatment of complex sleep disorders. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940762     DOI: 10.1159/000026676

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  19 in total

Review 1.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

2.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 3.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

4.  Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.

Authors:  Jennifer L Vande Voort; Elizabeth D Ballard; David A Luckenbaugh; Rebecca A Bernert; Erica M Richards; Mark J Niciu; Lawrence T Park; Rodrigo Machado-Vieira; Wallace C Duncan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

Review 5.  Beyond Ockham's razor: redefining problem-solving in clinical sleep medicine using a "five-finger" approach.

Authors:  David E McCarty
Journal:  J Clin Sleep Med       Date:  2010-06-15       Impact factor: 4.062

6.  Pregnancy and postpartum antidepressant use moderates the effects of sleep on depression.

Authors:  Kristen C Stone; Amy L Salisbury; Cynthia L Miller-Loncar; Jennifer A Mattera; Cynthia L Battle; Dawn M Johnsen; Kevin E O'Grady
Journal:  Arch Womens Ment Health       Date:  2017-05-09       Impact factor: 3.633

7.  The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex.

Authors:  E K Lambe; G K Aghajanian
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

8.  Sleep quality varies as a function of 5-HTTLPR genotype and stress.

Authors:  Beverly H Brummett; Andrew D Krystal; Allison Ashley-Koch; Cynthia M Kuhn; Stephan Züchner; Ilene C Siegler; John C Barefoot; Edna L Ballard; Lisa P Gwyther; Redford B Williams
Journal:  Psychosom Med       Date:  2007-08-31       Impact factor: 4.312

9.  Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study.

Authors:  Nikkie Aarts; Lisette A Zuurbier; Raymond Noordam; Albert Hofman; Henning Tiemeier; Bruno H Stricker; Loes E Visser
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

10.  Eszopiclone: its use in the treatment of insomnia.

Authors:  Jaime M Monti; S R Pandi-Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.